Convatec reports 5.0% organic revenue growth in H1 2026
Operating margin is 21.2% and adjusted EPS rises 6.3% to 8.5c. It confirms FY26 guidance, narrows ex-InnovaMatrix growth to 5.5-6.5% and announces a $200m share buyback.
See the latest news and media coverage for Convatec. We track all announcements, press releases, and industry mentions in real time, all in one place.
Chronic care medical products and technologies company
convatecgroup.comLast updated
In short: Convatec planned a £500 million Manchester R&D hub over the next decade
Operating margin is 21.2% and adjusted EPS rises 6.3% to 8.5c. It confirms FY26 guidance, narrows ex-InnovaMatrix growth to 5.5-6.5% and announces a $200m share buyback.
The programme commenced on 4 August 2026, with daily transaction details including volumes and weighted average prices in pence.
Reported revenue growth is 5.5% and FY26 guidance is unchanged, expecting 5-7% organic growth excluding InnovaMatrix, with growth to accelerate in H2.
It forecasts higher sales growth across all four categories, mid-20s operating margin and double-digit EPS growth.
10:54am ConvaTec to Spend GBP500 Million on New Global R&D Hub in Manchester, England, Over Next Decade MT 10:17am ConvaTec to Spend GBP500 Million on...
A big non-cash impairment of $69mn (£52mn) made the reported half-year results for wound-care and ostomy company ConvaTec (CTEC) look ugly, as the company wrote...
August 4 (Reuters) - British medical products maker Convatec (CTEC.L), opens new tab on Tuesday forecast its second-half operating margin to be materially higher than...
Convatec Group (CTEC.L) on Thursday detailed its new strategic plan to help achieve its aims of fast-tracking "sustainable and profitable" growth and reaching recently upgraded...
Track Convatec and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Convatec and other trending companies.